BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/20/2014 8:36:00 AM | Browse: 488 | Download: 434
Publication Name World Journal of Clinical Urology
Manuscript ID 10897
Country/Territory Japan
Received
2014-04-25 11:21
Peer-Review Started
2014-04-29 09:47
To Make the First Decision
2014-05-23 15:12
Return for Revision
2014-05-27 10:16
Revised
2014-06-05 16:19
Second Decision
2014-07-17 14:21
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2014-07-17 14:39
Articles in Press
2014-07-17 14:55
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2014-11-17 08:40
Publish the Manuscript Online
2014-11-19 17:43
ISSN 2219-2816 (online)
Open Access
Copyright
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Medicine, General and Internal
Manuscript Type Review
Article Title Benefits and risks of erythrocyte-stimulating agents
Manuscript Source Invited Manuscript
All Author List Daisuke Katagiri and Fumihiko Hinoshita
Funding Agency and Grant Number
Corresponding author Fumihiko Hinoshita, MD, PhD, Department of Nephrology, National Center for Global Health and Medicine, 1-21-1 Toyama Shinjuku-ku, Tokyo 162-8655, Japan. fhinoshi@hosp.ncgm.go.jp
Keywords Chronic kidney disease; Erythrocyte-stimulating agents; Renal anemia; Erythropoietin; Pure red cell aplasia
Core Tip Renal anemia is a common clinical problem in patients with severe chronic kidney disease. To overcome the shortage of endogenous erythropoietin (EPO), administration of exogenous EPO is an effective treatment. The advent of recombinant human erythropoietin (rHu-EPO) products has dramatically changed the therapeutic strategy and has shown outstanding effectiveness in patients with renal anemia. Here we discuss the treatment of renal anemia and the adverse effects of rHu-EPO.
Publish Date 2014-11-19 17:43
Citation Katagiri D, Hinoshita F. Benefits and risks of erythrocyte-stimulating agents. World J Clin Urol 2014; 3(3): 258-263
Url http://www.wjgnet.com/2219-2816/full/v3/i3/258.htm
DOI http://dx.doi.org/10.5410/wjcu.v3.i3.258
Full Article (PDF) WJCU-3-258.pdf
Full Article (Word) WJCU-3-258.doc
Manuscript File 10897-Review.docx
Answering Reviewers 10897-Answering reviewers.pdf
Copyright License Agreement 10897-Copyright assignment.pdf
Peer-review Report 10897-Peer review(s).pdf
Scientific Misconduct Check 10897-CrossCheck.jpg
Scientific Editor Work List 10897-Scientific editor work list.pdf